Compare Angi Inc (ANGI) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance

ANGI trades at $4.315, down 5.99% in the last session, reflecting ongoing operational challenges. The stock shows bearish technical signals with support near $4.00 and resistance at $5.00. Recent Q2 2026 earnings missed expectations with a significant EPS loss of $5.70, while revenue declined 11% year-over-year. Despite a low P/E of 14.81 and P/S of 0.19, negative net income margin of -22.35% and ROE of -26.25% highlight profitability struggles. Analyst consensus remains mixed with a $7.00 price target but accelerating pro user churn and legal investigations cloud the outlook.

The outlook for ANGI is cautious due to declining revenue, persistent losses, and competitive pressures. Investment opportunity exists if the company successfully executes its AI pivot and stabilizes user engagement, but risks include ongoing legal probes, high debt, and market share erosion. Near-term volatility is likely amid weak fundamentals and negative sentiment.

Tripadvisor (TRIP) trades at $10.695, down 0.79% on the day, reflecting persistent pressure from recent earnings misses and competitive challenges. The stock shows a bearish technical bias with weak moving averages, though oversold RSI levels hint at potential near-term support. Fundamentally, revenue growth is modest at $1.89B in 2025, but net margins remain thin at 0.27%, and a high P/E of 127.18 signals elevated expectations relative to earnings. The pending $700M sale of TheFork provides a liquidity boost but does not fully offset core business headwinds from AI-driven travel competition.

Outlook is cautious; while the stock trades below the consensus price target of $13.29, offering theoretical upside, investor sentiment is tempered by consecutive earnings misses and market share erosion. Key risks include stiff competition from AI travel tools, macroeconomic sensitivity, and execution challenges in revitalizing growth. Analysts are predominantly neutral (62.5% Hold), suggesting limited conviction in near-term catalysts despite the stock's current discount to target.